KAKhaled J. Alkhateeb

Khaled J. Alkhateeb

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Khaled J. Alkhateeb has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • TTF-1 Is a Sensitive and Specific Immunohistochemical Marker for Autoimmune Gastritis

    by Deepa Mbbs Kumari, Fazilet Yilmaz, Dongfang Yang, Li J. Wang, Evgeny Yakirevich, Murray B. Resnick, Khaled J. Alkhateeb

    Autoimmune gastritis (AIG) is an inflammatory disorder that leads to corpus-restricted mucosal atrophy and is associated with the formation of well-differentiated neuroendocrine tumors and, possibly, gastric adenocarcinoma. The early histologic findings of disease are not specific, and the diagnosis may require correlation with autoantibody serology. Recent evidence demonstrated the upregulation of lung differentiation genes in AIG. Here, we assess the expression of TTF-1, a marker of lung differentiation, in 75 biopsies of AIG, 36 biopsies of multifocal atrophic gastritis (MAG), 29 biopsies of Helicobacter pylori gastritis, 10 biopsies of reactive gastropathy, and 10 normal gastric biopsies. TTF-1 was expressed in metaplastic mucinous glands in 52 (69.3%) corpus biopsies of AIG, with most showing at least moderate-intensity (2+) staining. TTF-1 staining was frequently observed in biopsies with partial atrophy (75%) and in those without intestinal metaplasia (66.7%) or enterochromaffin-like (ECL) cell hyperplasia (66.7%). Two (5.6%) corpus biopsies with MAG demonstrated focal weak (1+) TTF-1 expression. ECL cells and antral mucosa were consistently negative for TTF-1. Staining was absent in all other study groups. The sensitivity and specificity of TTF-1 for AIG were 69.3% and 97.7%, respectively. When at least moderate-intensity staining (2+) was considered positive, TTF-1 was 61.3% sensitive and 100% specific for AIG. These findings demonstrate that immunohistochemistry for TTF-1 can be used to confirm the diagnosis of AIG, particularly in the absence of typical histologic features of established disease, and that it may reduce the need for confirmatory serologic tests in the earlier histologic phases of disease.

  • Open Access

    Aurora-A kinase is differentially expressed in the nucleus and cytoplasm in normal Müllerian epithelium and benign, borderline and malignant serous ovarian neoplasms

    by Khaled J. Alkhateeb, Jason E. Crane, Müge Sak, Caitlin J. Jorgensen, James P. O’dOnnell, Cory T. Zumbar, Jason A. Wozniak, Clarence R. Salazar, Anil V. Parwani, Norman L. Lehman

    Background: Aurora-A kinase is important for cellular proliferation and is implicated in the tumorigenesis of several malignancies, including of the ovary. Information regarding the expression patterns of Aurora-A in normal Müllerian epithelium as well as benign, borderline and malignant epithelial ovarian neoplasms is limited. Methods: We investigated Aurora-A expression by immunohistochemistry in 15 benign, 19 borderline and 17 malignant ovarian serous tumors, and 16 benign, 8 borderline, and 2 malignant ovarian mucinous tumors. Twelve fimbriae from seven patients served as normal Müllerian epithelium controls. We also examined Aurora-A protein expression by western blot in normal fimbriae and tumor specimens. Results: All normal fimbriae (n = 12) showed nuclear but not cytoplasmic Aurora-A immunoreactivity by immunohistochemistry. Benign ovarian tumors also showed strong nuclear Aurora-A immunoreactivity. Forty-eight percent (13/27) of borderline tumors demonstrated nuclear Aurora-A immunoreactivity, while the remainder (52%, 14/27) lacked Aurora-A staining. Nuclear Aurora-A immunoreactivity was absent in all malignant serous tumors, however, 47% (8/17) demonstrated perinuclear cytoplasmic staining. These results were statistically significant when tumor class (benign/borderline/malignant) was compared to immunoreactivity localization or intensity (Fisher Exact Test, p < 0.01). Western blot analysis confirmed the greater nuclear Aurora-A expression in control Müllerian epithelium compared to borderline and malignant tumors. Conclusion: Aurora-A kinase is differentially expressed across normal Müllerian epithelium, benign and borderline serous and mucinous ovarian epithelial neoplasms and malignant serous ovarian tumors., with nuclear expression of unphosphorylated Aurora-A being present in normal and benign neoplastic epithelium, and lost in malignant serous neoplasms. Further studies of the possible biological and clinical implications of the loss of nuclear Aurora-A expression in ovarian tumors, and its role in ovarian carcinogenesis are warranted.


  • Comparison between two types of needles for Endoscopic Ultrasound (EUS)‐guided fine aspiration biopsy of pancreatic and upper gastrointestinal masses

    by Khaled Alkhateeb, Beatrice B. Lee, Houda Alatassi, Mary A. Sanders, Endashaw M. Omer, Stephen A. McClave, Mostafa Fraig

    Background EUS‐guided fine‐needle aspiration (FNA) has long been the main method for sampling pancreatic lesions. Recently, the method of fine‐needle biopsy (FNB) was introduced in practice, allowing for the acquisition of tissue cores while aspirating the lesion. We hereby report our experience with a new FNB needle compared with the standard FNA needle. Methods Retrospective data from our department were collected on patients who underwent FNB using the Acquire EUS‐FNB needle (Boston Scientific, Massachusetts) and FNA using the EchoTip Ultra EUS‐FNA Needle (Cook Medical, Indiana) between January 2017 and February 2018. The cases were reviewed independently by two cytopathologists and evaluated for the presence of cell block or core tissue material, adequacy for potential ancillary testing, and number of passes. Results The number of passes ranged from 1 to 16, with a mean of 5.52 ± 3.74 in the FNA group, and from 1 to 6, with a mean of 2.74 ± 1.11 passes in the FNB group (P < .0001). Tissue cores were present in 87.23% of the FNB needle samples. A cell block was adequate in 36.36% of cases using the FNA needle. The diagnostic yield as well as the adequacy for ancillary testing were significantly different between the two groups (P = .0001). The tumor size, location and patients' demographics were not statistically significant between the two groups. Conclusion Compared with the conventional needle, the new FNB needle was associated with a lower number of passes and a better yield for histological material.